STOCK TITAN

Cytek Biosciences, Inc. Stock Price, News & Analysis

CTKB Nasdaq

Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.

Cytek Biosciences, Inc. (CTKB) delivers advanced cell analysis solutions through its patented Full Spectrum Profiling technology, serving research institutions and biotech organizations worldwide. This page provides investors and industry professionals with direct access to official company announcements and relevant news updates.

Discover the latest developments including product innovations, financial results, strategic partnerships, and regulatory milestones. Our curated collection ensures you stay informed about CTKB’s progress in advancing high-resolution cellular analysis tools for scientific research.

Key updates cover earnings reports, technology enhancements, executive leadership changes, and market expansion initiatives. All content is sourced from verified channels to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Cytek Biosciences’ evolving story in life sciences innovation. Check back regularly for real-time updates that matter to stakeholders in the biotech investment community.

Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) will participate in the 31st Annual Credit Suisse Healthcare Conference on November 9th, presenting at 3:50 PM PT / 6:50 PM ET. The presentation will be accessible via a live and archived webcast on the company’s website. Cytek specializes in cell analysis solutions through its innovative Full Spectrum Profiling™ technology, enhancing cell analysis precision and sensitivity. Products are primarily for research use, with some clinical use in approved regions. For more, visit cytekbio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
conferences
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) announced its participation in the 20th Annual Morgan Stanley Global Healthcare Conference on September 14, 2022, at 11:45 a.m. ET. A live webcast will be available on its website for interested parties. Cytek is a leader in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP™) technology for advanced cell analysis tools. Its product lineup includes the Aurora and Northern Lights systems and a comprehensive suite of reagents, software, and services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
conferences
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) reported a strong second quarter for 2022, with total revenue reaching $40.2 million, a 32% increase from the previous year.

The gross profit stood at $24.6 million, marking a 24% rise compared to Q2 2021, although the gross profit margin decreased to 61% from 65%.

Despite operating expenses rising 60% to $25.5 million, the company expects full-year revenue to be at the higher end of $160 million to $168 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
Rhea-AI Summary

Cytek Biosciences, a leader in cell analysis solutions, will participate in the 42nd Annual Canaccord Genuity Global Growth Conference in Boston on August 11, 2022, at 8:00 AM PT. The event will feature a fireside chat with company management, accessible via a live and archived webcast on their website. Cytek's innovative Full Spectrum Profiling technology enhances cell analysis precision and sensitivity. Its products are primarily for research use and have received regulatory approvals in some regions. More details are available on their investor relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
conferences
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) will report its second quarter 2022 financial results after market close on August 10, 2022. A conference call will follow on the same day at 2:00 p.m. PT to discuss the results and future outlook. Cytek is a leader in cell analysis solutions, known for its Full Spectrum Profiling™ (FSP™) technology, which enhances cell analysis precision and multiplexing capabilities. Its FSP platform includes instruments like Aurora and Northern Lights™ and reagents tailored for research purposes only. For more details, visit their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
conferences earnings
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) will host its inaugural Analyst and Investor Day on June 22, 2022, starting at 9:00 a.m. ET. This event aims to showcase Cytek's proprietary cell analysis technologies and related market opportunities, featuring presentations from industry leaders and Q&A sessions with the leadership team. A live webcast of the event will be available on Cytek’s investor relations website, and a replay will follow. Cytek specializes in Full Spectrum Profiling technology, enhancing cell analysis tools.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.17%
Tags
conferences
Rhea-AI Summary

Cytek Biosciences has announced the availability of its CE-IVD-certified cFluor reagents for clinical diagnostics across Europe. This certification allows Cytek to expand its market presence and offer total cell analysis solutions in hospitals and laboratories. The reagents are produced under rigorous quality controls and validated for optimal performance with Cytek's advanced cell analysis systems. CEO Dr. Wenbin Jiang emphasized the significance of this milestone, indicating a commitment to enhancing diagnostic capabilities across the region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
none
-
Rhea-AI Summary

Cytek Biosciences reported a strong first quarter for 2022, with total revenue reaching $35.1 million, marking a 44% increase year-over-year. The installed base grew to 1,226 instruments after placing 116 instruments in the quarter. Gross profit also rose to $20.2 million, though the gross profit margin slipped to 58% from 60% in 2021. Operating expenses climbed to $22.5 million, leading to a $2.4 million loss from operations. The company forecasts full-year revenue at the high end of $160 million to $168 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
-
Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) will report its Q1 2022 financial results after market close on May 11, 2022. Following the earnings announcement, management will host a webcast conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results, business developments, and future outlook. Cytek is known for its Full Spectrum Profiling™ technology, providing advanced cell analysis solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
conferences earnings
Rhea-AI Summary

Cytek Biosciences announces the appointment of Todd Garland as Chief Commercial Officer, effective immediately. Garland, with extensive experience in the life sciences sector, previously held leadership roles at BD Biosciences, CareFusion, and Cardinal Health. His expertise is expected to enhance Cytek's growth and customer service capabilities centered around their Full Spectrum Profiling™ (FSP™) technology. Dr. Wenbin Jiang, CEO, believes Garland's leadership will be pivotal in executing growth opportunities and fortifying the organization’s market position in cell analysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
management

FAQ

What is the current stock price of Cytek Biosciences (CTKB)?

The current stock price of Cytek Biosciences (CTKB) is $3.76 as of July 3, 2025.

What is the market cap of Cytek Biosciences (CTKB)?

The market cap of Cytek Biosciences (CTKB) is approximately 449.6M.
Cytek Biosciences, Inc.

Nasdaq:CTKB

CTKB Rankings

CTKB Stock Data

449.64M
114.96M
8.9%
61.33%
2.69%
Medical Devices
Laboratory Analytical Instruments
Link
United States
FREMONT